vTv Therapeutics to Participate in Investor Conferences in September.

vTv Therapeutics, a biopharmaceutical company, announced management participation in two investor conferences in September. The company is focused on developing cadisegliatin, a novel oral adjunctive therapy for type 1 diabetes. Management will participate in 1x1 investor meetings and a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference.

HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), announced today that it has entered into a purchase agreement for an $80 million private placement in public equity (“PIPE”) financing with leading healthcare institutional investors and the T1D Fund: A Breakthrough T1D Venture, LLC (“T1D Fund”). The PIPE financing is subject to customary closing conditions and is expected to close on or around September 3, 2025.

The proceeds from this financing will be used to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin. Topline data from the CATT1 Phase 3 trial is on track for release in the second half of 2026.

The investors in the financing include existing investors in the Company: a life sciences-focused institutional investor, Samsara BioCapital, L.P. (“Samsara”), and the T1D Fund. New investors include Trails Edge Capital Partners and Invus. TD Cowen and Evercore ISI are acting as lead placement agents for the PIPE financing.

Pursuant to the terms of the purchase agreement, vTv Therapeutics is selling to the investors units consisting of an aggregate of 682,018 shares of the Company’s Class A Common Stock and pre-funded warrants to purchase 4,561,714 shares of the Company’s Class A Common Stock, with accompanying warrants to purchase an aggregate of 5,243,732 shares of the Company’s Class A Common Stock. The purchase price for a unit consisting of one share of Class A Common Stock and an accompanying warrant is $15.265, and the purchase price for a unit consisting of one pre-funded warrant and an accompanying warrant is $15.255. The exercise price of the accompanying warrants is $22.71 per share.

Paul Sekhri, Chairman, President, and Chief Executive Officer of vTv Therapeutics, stated, “This financing enables us to continue advancing the development of cadisegliatin, including the CATT1 trial, which is evaluating the potential of cadisegliatin to help reduce the frequency of level 2 and 3 hypoglycemic events and to improve glycemic control in people living with T1D. It will also provide additional runway for the Company following topline data from the study, which is expected in the second half of 2026.”

Elizabeth Mily, CEO of the T1D Fund, added, “We are pleased to support vTv as they advance cadisegliatin through the CATT1 Phase 3 trial for people with type 1 diabetes. This funding will enable further investigation of cadisegliatin as an adjunctive therapy to insulin, with the potential to address persistent challenges in glycemic management. The T1D Fund exists to accelerate the development of T1D treatments, prevention, and cures, and this milestone represents meaningful progress on that path.”

Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

In addition to this funding announcement, vTv Therapeutics has also announced management participation in two investor conferences in September. Management will participate in 1x1 investor meetings and a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference.

References
[1] https://www.globenewswire.com/news-release/2025/09/02/3142624/0/en/vTv-Therapeutics-Announces-80-Million-Private-Placement-with-Leading-Healthcare-Institutional-Investors-and-the-T1D-Fund.html
[2] https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-80-million-private-placement-leading